Drugs in Dev. Oncology
Discovery
Canada 
Rakovina Announces the Closing of Oversubscribed Private Placement of $4.9 Million
Details : The financing aims to fund the clinical development of KT-2000, which is being evaluated in discovery stage for the neoplasms.
Product Name : KT-2000
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 06, 2025
Alpha-9 Oncology Raises $175M to Advance Radiopharmaceutical Pipeline
Details : The proceeds will advance the pipeline of targeted radiopharmaceuticals through clinical studies across multiple tumors and discovery stage assets to clinic-ready development candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 23, 2024
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration
Details : The collaboration aims to leverage OpenBench's approach for early drug discovery against an undisclosed target identified by ORIC's resistance platform, focusing on cancer-specific vulnerabilities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
Details : The net proceeds will be used to fund the advancement of research and development of Rakoniva AI drug-discovery product KT-2000 for the treatment of neoplasms.
Product Name : KT-2000
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2024
Rakovina Announces Oversubscribed Private Placement and 2024 Annual Meeting Results
Details : The net proceeds will be used to fund the advancement of research and development of Rakoniva AI drug-discovery product KT-2000 for the treatment of neoplasms.
Product Name : KT-2000
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 20, 2024
Details : The collaboration will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines important i...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $9.0 million
November 29, 2023
Details : Under the collaboration, AbCellera and Incyte will discover and develop therapeutic antibodies in oncology and Incyte will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 13, 2023
Details : The collaboration will combine ImmunoGen's proprietary linker-payload technology with ImmunoBiochem's antibodies directed against specific targets to develop next-generation antibody-drug conjugates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 24, 2023
Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Details : The multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s AI-enabled screening platform to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 27, 2023
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
Details : The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 29, 2022
Reset All
